Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Huh?!
P.T. Barnum said you can never go broke underestimating the intelligence of the American public.
Nowadays that translates into:
You can never go broke underestimating the CONSCIOUSNESS of the public.
Increased brain fog, increased dopamine from avid scrolling of computer and cell phone screens, etc.
Seems our brains are being chemically tittalated whilst weaving in and out of the brain fog.
Well, as long as enough of the people can be fooled enough of the time, we will be in a temporarily insufficient state of awareness.
As we emerge from that state, if we have opportunity within which to do so....Star Trek?
Thanks for the article recommendation.
Correct, you have to leverage a big numbers game. Mitigating “hit-and-miss” with brute force, tolerance to risk, and ignoring the urge to short-term profit at the detriment of long-term progress. It’s a necessary, deliberate choice of strategy.
From my perspective if you are putting together an archery team, you select the members based upon who is closest to the bullseye. Hence why you see many preclinical and early clinical development deals. BP can afford a few misses as long as they get one that nails the bullseye in company making fashion.
You make a very good point. Hence why some would consider this gambling like most OTC or speculative stocks/industries.
Odds of scoring a touchdown in pharma industry is low; RSPI in some sense just needs to get the ball in field goal range.
A recent PR suggested they were waiting to maybe later in the year to pursue further the SCI/ADHD program. OSA program has many others seeking that solution as well as questions around utilizing cannibas or synthetic related compounds. They have given the impression they are doing preclinicals there, but no recent update.
The pain/epilepsy candidate feels just a bit different to me. I think NIH has an important/meaningful task in regards to opioids that bypasses the shenangins within the majority of the political arena. The confidence and excitement, and commentary from outside reputable perspectives in regards to progress with epilepsy and pain on this candidate I think is hard for them to mask. It is hard for retail positions to gauge progress, but I kinda feel they have completed a few first downs and are driving the ball.... IMO
Developing drugs that are actually useful for helping mental, psychological, emotional problems is a bit like being a blind sniper! So there’s a reason Big Pharma is floundering, generally. Huge uncertainty, and basic problems with statistical methods means that you can’t design such treatment like you would design a car, or an airplane. It requires much more “groping in the dark”.
If you are up for a challenging, but accessible account of some of origins of the disconnection that currently plagues basic neuroscience, and the medical/psychiatry toolkit that is obviously largely not living up to it’s potential, try this!:
https://www.wsj.com/articles/the-world-behind-the-world-review-what-the-brain-scan-misses-6033e7ad
1. Given the nefarious recent history of scientific research being a deliberate sham to get government funding...some say as much as 99% of it
2. Obviously earned distrust of pols by non pols, extending sometimes to alphabet govt. Agencies...no disregard for govt. Workers...
3. Given the nefarious history of OTC stocks as a pump and dump...repeat...territory
Is it possible so many are jaded and just doubtful of such a government agency [nih], aiding an effort for a non-opiode pain disintegrating drug...
"REALLY?...AND BIG PHARMA WILL BE OKAY WITH ONLY ONE BP WINDING UP WITH THIS UNTIL GENERICS CAN MAKE THE SCENE"...I hear some saying in my imagination.
"Oh! And a drug to replace sleep apnea machines and constant flow of cpap machine supplies, too?"
"OH, and an anti-convulsant for epilepsy sufferers with no side effects and more?!?!"
"Please tell me there is a bridge in Brooklyn as an extra added asset for which tolls can be charged?"
Just researching all of the sham in the arenas that RSPI is in, presumably with integrity makes e1 but a few of us already invested, looking and waiting b4 jumping in?
It really does sound too good to be true, doesn't it?
And the proof of the pudding is in the tasting, isn't it?
Just waiting for it to be sufficiently tasted.
We are a true minority of invested believers.
Is RSPI the only penny stock?
New May 2, 2024 mention of RespireRx RSPI:
Spinal Cord Injury Therapeutics Market See Incredible Growth 2024-2031 | Teva Pharmaceutical Industries Ltd., AbbVie Inc, Pfizer Inc
05-02-2024 01:57 PM CET | Health & Medicine
Press release from: Coherent Market Insights
“Key Players Covered In This Report:
Teva Pharmaceutical Industries Ltd., AbbVie Inc, Pfizer Inc., Reddy's Laboratories Ltd, Zydus Cadila, ReNetX Bio, Inc, InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc, Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc, RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc, ScieGen Pharmaceuticals, Inc, MSN Laboratories Private Limited, and Lannett Co Inc.”
https://www.openpr.com/news/3482860/spinal-cord-injury-therapeutics-market-see-incredible-growth
Well with minimal liquity on most OTC equities, the movement of the MM's is really just on a whim here and there and a few traders with small money interest can influence. So IMO, nothing real can be gleened from that with minimal volume.
I think the investment thesis here is rather simple. Either you are long and believe in the possibilities of their drug programs and current progress setting up for BP or similar deals, or you don't. If they cant create value with their programs then this flounders. If they do create valuae and strike a major deal, this will be a hard one to catch and will be one of those long rememebered story stocks of the OTC. IMO.
Moved up but still hanging around...gotta get big volume.
OTCN parked at .0009...smh.
Interesting oldstocks.. thanks !! for all you do in every board buddy.
I believe this helps clear the path for human clinicals in the US for their OSA program. So that is good news.
They do their interviews with I believe it is a PR group called proactiveinvestors.com where you can search RespireRx and find related PR/interviews.
Not sure why they dont publicize or promote these interviews further as it does seem to provide a more candid view of everything.
The US Drug Enforcement Administration plans to reclassify marijuana as a less dangerous drug, a historic shift in US drug policy.
https://www.bbc.com/news/world-us-canada-68932612#;
Reclassification could also make government-authorised clinical studies of the drug's medical benefits easier.
Industry groups have also suggested that it could help ease the tax burden on businesses in the cannabis industry, which can rise to 70% in some cases.
Thanks LTListener, is there video link of thi s interview. Is it on their website? Thanka
Matter of time here, patience to pay off nicely IMO
$RSPI
But still in .000s..we are missing something here.
And the biggest turds are running.
RSPI keeps getting out there with the big boys.
And:
Attention Deficit Hyperactivity Disorder (ADHD) Market Size, Share & Trends Analysis, By Drug Type (Stimulants, Non-stimulants), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy), By Demographics, By Region and Forecast Period 2023 – 2030 (Updated Version Available)
Report ID - MRC_3748 | Pages - 209 | Category - Healthcare and Pharma
“Key Players: Adlon Therapeutics L.P., Amnel Pharmaceuticals LLC., Aytu Biopharma Inc., American Brivision (Holding) , Corporation, Cingulate Inc., Eli Lilly And Company, GSK plc, Johnson & Johnson Services Inc., Neos Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc, Otsuka Pharmaceutical Co. Ltd, Purdue Pharma L.P., RespireRx Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Tris Pharma Inc.”
https://marketresearchcommunity.com/attention-deficit-hyperactivity-disorder-adhd-market/?trk=article-ssr-frontend-pulse_little-text-block
Other mention in current market report:
Circadian Rhythm Sleep Disorders Market Robust Expansion by Top Key Manufactures, Demand and Supply to 2029
“Leading Circadian Rhythm Sleep Disorders manufacturers/companies operating at both regional and global levels:
Arena Pharmaceuticals Boehringer Ingelheim Fabre-Kramer Pharmaceuticals Jazz Pharmaceuticals Merck & Co Glaxo Smith Kline Respirerx Pharmaceuticals Neurocrine Biosciences”
https://www.pharmiweb.com/press-release/2020-08-31/circadian-rhythm-sleep-disorders-market-robust-expansion-by-top-key-manufactures-demand-and-supply-1
New market research report, Muscle disorders, May 2024:
Global Chorea Treatment Market Size And Forecast
Report ID : 444919 | Published : May 2024 | Study Period : 2021-2031 | Pages : 220+ | Format : PDF + Excel
“ Key Players in the Chorea Treatment Market
The Chorea Treatment Market Report offers a detailed examination of both established and emerging players within the market. It presents extensive lists of prominent companies categorized by the types of products they offer and various market-related factors. In addition to profiling these companies, the report includes the year of market entry for each player, providing valuable information for research analysis conducted by the analysts involved in the study.
Medtronic
Boston Scientific
Aleva Neurotherapeutics
Teva Pharmaceutical
Pfizer
GlaxoSmithKline
Bausch Health Companies
LivaNova
Lundbeck
Ipsen
Alnylam Pharmaceuticals
Prana Biotechnology
RespireRx Pharmaceuticals
Vertex Pharmaceuticals
SOM Biotech”
https://www.marketresearchintellect.com/product/global-chorea-treatment-market-size-and-forecast/
More press:
Biotech, Pharmaceuticals & Genetics Industry Almanac 2024: Biotech, Pharmaceuticals & Genetics Industry Market Research, Statistics, Trends and Leading Companies
491 Pages
Plunkett Research Ltd
ID: 5411875
“ Companies Mentioned
23andMe Holding Co
3SBio Inc
4SC AG
Abbott Laboratories
AbbVie Inc
[…]
Repligen Corporation
RespireRx Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
[…]”
https://www.researchandmarkets.com/reports/5411875/biotech-pharmaceuticals-and-genetics-industry?utm_code=3j48w3&utm_exec=chdo54prd
You’re welcome
Hard to say. It is all speculation at this point.
All we can go off of is the CEO's recent interview a few months ago which expressed confidence in their drug candidate KRM-II-81 that is in tier 3 NIH preclinicals. There he suggested they would get grant money into human clinicals assuming the addicitive liability in the preclinicals is a positive progression. He also suggested they are looking for funding "pursestrings" support for the development, which can take many different shapes, but IMO something as significant as getting greenlighted into human clincals to mitigate the opioid crisis is big time and requires BP support if not fully taking the baton on the program. If that happens we likely are trading by nickels and dimes...Again all speculation but why else to invest in the OTC? Risk v. Reward
They claimed in PR to be waiting for funding for the ADHD/SCI drug candidate and the OSA program is in Australia and assuming waiting for preclincal work to complete, but again no recent update there either.
Would the next logical step for a pr announcement [ Not about drug progress, ] be a LOI emerging from the silence which seems to indicate networking betwixt 2 or more entities?
Of course, I am with you. All OTC stocks are gambles and about timing. Hence utilizing speculative investment money only.
I agree in that the risk v reward has huge potential here. Unlike most other OTC stocks, which only thrive on sometimes artificial momentum, RSPI has legit drug development programs with very promising potential and progress. This creates value. Considering they hired a VP to help and publicly talk about unlocking the value in these programs, it is logical to expect some type of negotiation(s) are in the works. Trading pattern and silence feels that was as well. Whether we get a large BP deal or funding instrument to further either of the 3 drug development programs is yet to be known.
Really interested in preclinical results of NIH trials as well as the new OSA formulations, either have potential to unlock substantial value and pps appreciation well beyond typical OTC imaginations.
If someone buys at the higher asking price it records as a buy. If someone gets the order filled on the lower priced bid it’s recorded as a sell. In short if traders are hitting the ask it’s buys. If they’re bid sitting it’s considered sells
Nice buys going thru...fuk off OTCN
How is that possible?
Isn't each buy a sell?
Yes sir. Loading up the boats before we set sail
8.9 million buys vs 1.4 million sells, accumulation picking up here.
$RSPI
Its a gamble but i am adding..just in case.If it pays off its going to be big.
RSPI getting ready for a move
Nice action today, and the sharp short interest downturn makes this ticker’s wacky behavior made some sense, with the benefit of hindsight.
Folks can chime in an correct, but my take is their new formulations for dronabinol OSA trials are undergoing preclincal evaluations. Once these are complete, they hope to bypass some of the clinicals and move into phase 3 human trials, since dronabinol has been tested much in the past in clinical trials. Not sure where they are at on moving forward with this since there has been zero update along these lines. I kinda feel it makes sense to figure out what they are doing with NIH and possible BP involvement there before moving forward too much with the other programs, since funding capacity will be dictated by such.
It does seem awfully quiet with no effort on 10-k and no recent communications all things considered.
good luck to us all...
Maybe, maybe not. I think anything different than status quo sometimes is interesting.
Jump in volume. Ignoring the 10-k completely. Silence. All could be positive or negative in the end. Logically, though, one would think any preclinicals on the OSA side would be making progress and nearing some advancement.
The bigger fish is the KRM-II-81 progress in tier 3 NIH preclinicals. No word on this progress, but one would think there would be preliminary indications as to whether or not the rats/animals show any addictive liability to the drug. If they move forward, I am curious if NIH would strongly encourage getting this into BP hands and out of OTC world, especially considering no depth in management nor any active CEO in place to manage grant funding for human trials.
The possibilities here are flat out enormous considering the positive progress along multiple drug development paths. IMO, deserving much much higher speculative valuation at minimum. Whether or not they have the goods to get across the goal line is still unknown. Feels like an extended time out to decide how to proceed. A progress update would be beneficial here, IMO.
Like final phase 3 ...pre human clinical, or just an interim progress report?
Phase 3 news close, some are impatient. Nice opps in this range IMO
$RSPI
I’m with you… I don’t post much either, but I continue to hold… and I just grabbed a few more this morning, since I like what I am seeing. Best of luck!💪🏻
Starting to get interesting .0012s up...
Nice to see it up 11% since i am holding just under 10 million shares.
I don’t post much over here but i watch and read.
Followers
|
345
|
Posters
|
|
Posts (Today)
|
16
|
Posts (Total)
|
51294
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators DTGoody crazy horse 0 fly_fisherman Lime Time archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
Form Type | Received | Period End Date | Report |
---|---|---|---|
8-K | 07/08/2024 | 07/02/2024 | PDFRTFHTMLXLS |
8-K | 05/29/2024 | 05/29/2024 | PDFRTFHTMLXLS |
8-K | 04/16/2024 | 04/10/2024 | PDFRTFHTMLXLS |
NT 10-K | 04/01/2024 | 12/31/2023 | PDFRTFHTMLXLS |
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |